<DOC>
	<DOCNO>NCT03082846</DOCNO>
	<brief_summary>Postoperative conventional radiation 60 Gy/30f currently still consider standard radiotherapy mode high-grade glioma ; however , efficacy still unsatisfactory . Studies recent year show hypofractionated simultaneous integrated boost-intensity modulate radiation therapy ( SIB-IMRT ) certain survival benefit fractionation method ; , best hypofractionation mode efficacy confirm . The purpose study investigate maximum tolerate dose ( MTD ) hypofractionated SIB-IMRT stepwise escalate dos combine temozolomide ( TMZ ) treatment malignant glioma .</brief_summary>
	<brief_title>Treatment High-grade Gliomas Using Hypofractionated Radiation Therapy -a Phase I Clinical Trial</brief_title>
	<detailed_description>Background : Postoperative conventional radiation 60 Gy/30f currently still consider standard radiotherapy mode high-grade glioma ; however , efficacy still unsatisfactory . Studies recent year show hypofractionated simultaneous integrated boost-intensity modulate radiation therapy ( SIB-IMRT ) certain survival benefit fractionation method ; , best hypofractionation mode efficacy confirm . The purpose study investigate maximum tolerate dose ( MTD ) hypofractionated SIB-IMRT stepwise escalate dos combine temozolomide ( TMZ ) treatment malignant glioma . Methods : Malignant glioma patient receive concurrent postoperative radiotherapy chemotherapy . The simultaneous integrated boost-intensity modulate technology adopt increase dose surgical cavity residual tumor ( PTV1 ) . The dose fraction gradually increase 2.8 Gy/f ( total 20 time ) escalate dose interval 0.4 Gy . The planning target volume ( PTV2 ) include 2cm region around surgical cavity residual tumor remain unchanged , 2.5 Gy time total 50 Gy/20f . The subsequent group patient advance next dose level dose-limiting toxicity ( DLT ) present . The dose , one level lower DLT , MTD . The high target single dose 4 Gy/f . TMZ administer orally every day 75 mg/m2 radiotherapy 150-200 mg/m2 12 cycle follow completion chemoradiotherapy .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Postoperative grade III IV glioma patient confirm pathology . 2 . The ages 1870 year . 3 . Karnofsky performance score（KSP）≧60 . 4 . Expected survival period ≧3 month . 5 . Blood routine liver kidney function normal . 6 . Receive cranial MRI examination 48 h surgery . 7 . Radiotherapy perform 24 week surgery . 8 . Patients restrict lesion nondiffuse growth . 9 . Maximum diameter residual tumor , surgical cavity , primary tumor bed ≦6 cm . 1 . Lesions brain stem thalamus . 2 . Pregnant lactating woman . 3 . Secondary primary malignant tumor . 4 . Severe pulmonary infection . 5 . Combination mental illness another disease require hospitalization . 6 . Patients receive chemotherapy brain radiotherapy previously .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>malignant glioma</keyword>
	<keyword>intensity modulate radiation therapy</keyword>
	<keyword>simultaneous integrate boost</keyword>
	<keyword>hypofractionation</keyword>
	<keyword>temozolomide</keyword>
	<keyword>maximum tolerate dose</keyword>
</DOC>